ABSTRACT
BACKGROUND: To explore the anti-osteoporosis and anti-diabetes effects and potential underlying mechanisms of treatment with metformin and alendronate in diabetes mellitus mice. METHODS: Eight-week-old C57 BL/KS db/db and db/+ female mice were evaluated according to the following treatment group for 12 weeks: control group, diabetes mellitus group, diabetes mellitus with metformin group, diabetes mellitus with Alendronate group, diabetes mellitus with metformin plus alendronate group. Glucose level, glucose tolerance test, bone mineral density, bone microarchitecture, bone histomorphometry, serum biomarkers, and qPCR analysis. RESULTS: Combined metformin and alendronate can improve progression in glucose metabolism and bone metabolism, including blood glucose levels, blood glucose levels after 4 and 16 hours fasting, glucose tolerance test results, insulin sensitivity and reduces bone loss than the diabetes group. The use of alendronate alone can increase significantly serum glucagon-like peptide-1 levels than the diabetes group. The use of metformin alone can improve bone microstructure such as Tb.Sp and Tb.N of spine in diabetic mice. CONCLUSION: The combined use of alendronate and metformin has an anti-diabetes and anti-osteoporotic effect compared with diabetic mice, but they appear to act no obvious synergistically between alendronate and metformin.
Subject(s)
Alendronate/therapeutic use , Bone Demineralization, Pathologic/prevention & control , Diabetes Mellitus/pathology , Glucose/metabolism , Metformin/therapeutic use , Alendronate/administration & dosage , Animals , Blood Glucose/drug effects , Bone Density/drug effects , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/therapeutic use , Diabetes Mellitus/drug therapy , Diabetes Mellitus/metabolism , Drug Therapy, Combination , Female , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Metformin/administration & dosage , Mice , Mice, Inbred NODABSTRACT
This study aimed to assess the influence of glycosaminoglycan (chondroitin and glucosamine sulfates) supplementation in the diet on the performance and incidence of locomotor problems in broiler chickens. A completely randomized design was carried out in a 3 × 3 factorial scheme (3 levels of chondroitin sulfate -0, 0.05, and 0.10%; and 3 levels of glucosamine sulfate -0, 0.15, and 0.30%). Each treatment was composed of 6 replications of 30 broilers each. The performance of broilers (average weight, weight gain, feed intake, feed conversion, and productive viability) was assessed at 7, 21, 35, and 42 d of age, whereas the gait score, valgus and varus deviations, femoral degeneration, and tibial dyschondroplasia were assessed at 21 and 42 d of age. Increasing levels of glucosamine sulfate inclusion linearly increased the weight gain from 1 to 35 and from 1 to 42 d of age of broilers (P = 0.047 and P = 0.039, respectively), frequency of broilers with no femoral degeneration in the right and left femurs, and the proliferating cartilage area of proximal epiphysis at 42 d of age (P = 0.014, P < 0.0001, and P = 0.028, respectively). The increasing inclusion of chondroitin and glucosamine sulfates led to an increase in the frequency of broilers on the gait score scale 0 (P = 0.007 and P = 0.0001, respectively) and frequency of broilers with no valgus and varus deviations (P = 0.014 and P = 0.0002, respectively) also at 42 d of age. Thus, chondroitin and glucosamine sulfates can be used in the diet of broiler chickens to reduce their locomotor problems.
Subject(s)
Chickens , Dietary Supplements , Glycosaminoglycans , Animal Feed/analysis , Animal Nutritional Physiological Phenomena/drug effects , Animals , Bone Demineralization, Pathologic/prevention & control , Bone Demineralization, Pathologic/therapy , Bone Demineralization, Pathologic/veterinary , Diet/veterinary , Glycosaminoglycans/pharmacology , Osteochondrodysplasias/prevention & control , Osteochondrodysplasias/therapy , Osteochondrodysplasias/veterinary , Random AllocationABSTRACT
Abnormal calcium metabolism in sarcoidosis patients can lead to hypercalcemia, hypercalciuria, and kidney stones. Hypercalcemia in sarcoidosis is usually due to increased activity of 1α-hydroxylase in macrophages of pulmonary granulomata, resulting in low levels of 25-hydroxyvitamin D and high levels of calcitriol. Vitamin D supplementation may be dangerous for some sarcoidosis patients and is recommended only for those with decreased 25-hydroxyvitamin D and reduced or normal calcitriol level. Diagnosis, treatment of osteoporosis, and maintenance of bone health are complex issues for sarcoidosis patients. An approach to diagnosis and treatment of bone fragility is presented.
Subject(s)
Bone Demineralization, Pathologic/metabolism , Calcium/metabolism , Dietary Supplements/adverse effects , Sarcoidosis/metabolism , Vitamin D/pharmacology , Age Factors , Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/prevention & control , Calcitriol/blood , Fractures, Bone/prevention & control , Humans , Medication Therapy Management , Pragmatic Clinical Trials as Topic , Risk Factors , Sarcoidosis/complications , Sarcoidosis/therapy , Sex Factors , Vitamin D/metabolismABSTRACT
Bone volume, microstructure and its material composition are maintained by bone remodelling, a cellular activity carried out by bone multicellular units (BMUs). BMUs are focally transient teams of osteoclasts and osteoblasts that respectively resorb a volume of old bone and then deposit an equal volume of new bone at the same location. Around the time of menopause, bone remodelling becomes unbalanced and rapid, and an increased number of BMUs deposit less bone than they resorb, resulting in bone loss, a reduction in bone volume and microstructural deterioration. Cortices become porous and thin, and trabeculae become thin, perforated and disconnected, causing bone fragility. Antiresorptive agents reduce fracture risk by reducing the rate of bone remodelling so that fewer BMUs are available to remodel bone. Bone fragility is not abolished by these drugs because existing microstructural deterioration is not reversed, unsuppressed remodelling continues producing microstructural deterioration and unremodelled bone that becomes more mineralized can become brittle. Anabolic agents reduce fracture risk by stimulating new bone formation, which partly restores bone volume and microstructure. To guide fracture prevention, this Review provides an overview of the structural basis of bone fragility, the mechanisms of remodelling and how anabolic and antiresorptive agents target remodelling defects.
Subject(s)
Anabolic Agents/therapeutic use , Bone Demineralization, Pathologic/prevention & control , Bone Density Conservation Agents/therapeutic use , Animals , Bone Demineralization, Pathologic/therapy , Bone Remodeling/drug effects , Bone Resorption/drug therapy , HumansABSTRACT
The aim of this study was to investigate if grape or apple juices are able to protect bone tissue of rats exposed to cadmium. For this purpose, histopathological analysis and immunohistochemistry for RUNX-2 and RANK-L were investigated in this setting. A total of 20 adult Wistar rats were distributed into four groups (n = 5), as follows: control group, cadmium group, cadmium and grape juice group, and Cadmium and apple juice group. Control group received a single intraperitoneal (i.p.) water injection. Cadmium group received a single i.p. injection of cadmium chloride (1.2 mg/kg body weight) diluted in water. Cadmium and grape juice and cadmium and apple juice groups received a single i.p. injection of cadmium chloride (1.2 mg/kg body), and after 15 days, the rats were treated with grape or apple juices for 15 days, by gavage. All animals were euthanized 30 days after the beginning of experiment. Histopathological analysis in rat femur revealed extensive bone loss in rats intoxicated with cadmium. Grape or apple juices were able to increase bone formation. Cadmium inhibited RUNX-2 immunoexpression whereas cadmium increased RANK-L immunoexpression in rat bone cells. Grape or apple juices increased RUNX-2 and decreased RANK-L immunoexpression after cadmium intoxication. Taken together, our results demonstrate that grape or apple juices are able to exert therapeutic activity following cadmium intoxication in rat bone tissue as result of stimulatory effect of bone formation by RUNX-2 upregulation and RANK-L downregulation.
Subject(s)
Bone Demineralization, Pathologic/prevention & control , Core Binding Factor Alpha 1 Subunit/genetics , Femur/drug effects , Fruit and Vegetable Juices , Osteogenesis/drug effects , Protective Agents/pharmacology , Receptor Activator of Nuclear Factor-kappa B/genetics , Animals , Core Binding Factor Alpha 1 Subunit/metabolism , Femur/pathology , Immunohistochemistry , Male , Malus/chemistry , Rats , Rats, Wistar , Receptor Activator of Nuclear Factor-kappa B/metabolism , Vitis/chemistryABSTRACT
PURPOSE OF REVIEW: Vitamin D supplementation is widespread used in the general population. In sarcoidosis, up to 50% of patients, especially postmenopausal women and those taking corticosteroids, show evidence of increased bone fragility. The purpose of this review is to provide an evidence-based rationale on how to treat sarcoidosis patients with bone health issues. RECENT FINDINGS: Evidence from observational studies show that decreased 25-hydroxy vitamin D is common in sarcoidosis. However, the great majority of sarcoidosis patents have normal or often elevated levels of 1,25-dihydroxy vitamin D (calcitriol), a marker associated with disease activity. High calcitriol levels may often be associated with hypercalcemia and hypercalcuria. The few interventional randomized controlled studies in the field, suggest that vitamin D supplementation may not be well tolerated because of hypercalcemia, moreover without substantial benefit on bone health and risk for fractures in these patients. SUMMARY: Vitamin D supplementation may be withheld in sarcoidosis patients with bone fragility, unless calcitriol levels are below normal limits. A treating scheme is proposed.
Subject(s)
Bone Demineralization, Pathologic , Calcium/metabolism , Dietary Supplements/adverse effects , Fractures, Bone/prevention & control , Sarcoidosis , Vitamin D , Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/metabolism , Bone Demineralization, Pathologic/prevention & control , Calcitriol/blood , Humans , Medication Therapy Management , Sarcoidosis/complications , Sarcoidosis/metabolism , Sarcoidosis/therapy , Vitamin D/metabolism , Vitamin D/pharmacologyABSTRACT
INTRODUCTION: Based on the essential role of vitamin D in the regulation of calcium metabolism, we evaluated the effects of 2000IUvitamin D/day in late pregnancy on infant's anthropometric measurements and bone mass parameters of mother-infant pairs. MATERIAL AND METHODS: In this randomized clinical trial, the main inclusion criteria were: aged 18 or older, no history of internal diseases and pregnancy complications, and a singleton live fetus. The intervention group received two 1000IU vitamin D3 pills (2000IU) daily from weeks 26-28 until childbirth. Maternal serum 25-hydroxyvitamin D, infants' anthropometric measurements (at birth, 4th and 8th weeks postnatal), and maternal and infant bone mass parameters were examined. RESULTS: The two groups were not statistically different in relation to baseline 25-hydroxyvitamin D concentrations. However, there was a significant difference between the study groups with regard to change in vitamin D status over time (p<0.001). In cross-sectional analysis, the two groups were not different with respect to anthropometric measurements in three time points. Also, in repeated measure analysis, the two groups did not show any statistical differences concerning the infants' anthropometric measurements. The bone mass measurements of all the 28 mothers who belonged to the two study groups were not different. Finally, the bones mass measurements of the infants in the two study groups were not different. CONCLUSION: Ingestion of 2000IUvitamin D3/day during late pregnancy did not improve anthropometric measurements of infants from birth until the 8th week postnatal, nor improve the maternal and infant bone mass measurements.
Subject(s)
Bone Demineralization, Pathologic/prevention & control , Bone Density/drug effects , Fetal Development/drug effects , Pregnancy Complications/prevention & control , Vitamin D/analogs & derivatives , Vitamins/therapeutic use , Adult , Birth Weight/drug effects , Female , Humans , Infant, Newborn , Male , Pregnancy , Vitamin D/administration & dosage , Vitamin D/pharmacology , Vitamin D/therapeutic use , Vitamins/administration & dosage , Vitamins/pharmacologyABSTRACT
Antecedentes: El inicio y la discontinuación del tratamiento antiparatiroideo son decisiones importantes en los pacientes en hemodiálisis crónica (HD) en los que la carga de pastillas es con frecuencia excesiva. El objetivo de este estudio es describir de tratamiento del hiperparatiroidismo secundario (sHPT) en pacientes en HD. Métodos: Estudio de cohorte, observacional retrospectivo de pacientes europeos incidentes en HD con sHPT a quienes se prescribió calcitriol o alfacalcidol (calcitriol-alfa), paricalcitol o cinacalcet. Resultados: Se incluyeron en el análisis pacientes que recibieron por primera vez calcitriol-alfa (N=2259), paricalcitol (N=1689) y cinacalcet (N=1245). Los valores sericos de hormona paratiroidea intacta (iPTH) disminuyeron tras iniciación con todos los tratamientos; los valores de calcio y fosforo serico se elevaron en respuesta al tratamiento con activadores de vitamina D pero disminuyeron con cinacalcet. Aproximadamente un tercio de los pacientes que recibieron calcitriol alfa y paricalcitol, y menos de una cuarta parte de los de cinacalcet discontinuaron el tratamiento. Aunque los tres grupos tuvieron descensos comparables de iPTH al momento de la interrupción del tratamiento, sin embargo difirieron en los valores de calcio y fosforo serico. Tras la interrupción, la evolución de los parámetros de laboratorio fué diferente según la modalidad de tratamiento: mientras que la iPTH se elevó en las tres modalidades, el calcio y fosforo sericos disminuyeron en los pacientes que estaban siendo tratados con calcitriol-alfa y paricalcitol en el momento de la interrupción y aumentaron en los que lo hacían con cinacalcet. Conclusiones: En condiciones clínicas que representan la práctica diaria, alcanzar y mantener los valores recomendados para el control del sHPT se consigue más frecuentemente con cinacalcet que con compuestos activos de vitamina D (AU)
Background: Anti-parathyroid treatment initiation and discontinuation are important decisions in chronic haemodialysis (HD) patients, where pill burden is often excessive. The present study aimed to describe secondary hyperparathyroidism (sHPT) drug therapy changes in HD patients. Methods: Retrospective observational cohort study of incident European HD patients with sHPT who were prescribed calcitriol or alfacalcidol (alpha calcitriol), paricalcitol or cinacalcet. Results: Treatment-naïve patients prescribed alpha calcitriol (N=2259), paricalcitol (N=1689) and cinacalcet (N=1245) were considered for analysis. Serum intact parathyroid hormone (iPTH) levels decreased post-initiation with all treatment modalities; serum calcium and phosphate levels increased in response to activated vitamin D derivatives but decreased with cinacalcet. Approximately one-third of alpha calcitriol and paricalcitol patients but less than one-quarter of cinacalcet patients discontinued treatment. Although the three groups had comparable serum iPTH control at the time of treatment discontinuation, they differed in terms of calcium and phosphate levels. Following discontinuation, the evolution of laboratory parameters differed by treatment modality: whilst iPTH increased for all three treatment groups, calcium and phosphate decreased in patients who were being treated with alpha calcitriol and paricalcitol at the time of discontinuation, and increased in those who had been treated with cinacalcet. Conclusions: In conditions of daily clinical practice, attaining and maintaining recommended biochemical control of sHPT appears to be more frequently achievable with cinacalcet than with activated vitamin D compounds (AU)
Subject(s)
Humans , Renal Insufficiency, Chronic/complications , Renal Dialysis/adverse effects , Hyperparathyroidism, Secondary/prevention & control , Bone Demineralization, Pathologic/prevention & control , Parathyroid Hormone/analysis , Retrospective StudiesABSTRACT
PURPOSE: The purpose of this paper was to review the literature concerning the treatment of chronic kidney disease-mineral bone disorder (CKD-MBD) in the elderly peritoneal dialysis (PD) patient. RESULTS: Chronic kidney disease-mineral bone disorder is a major problem in the elderly PD patient, with its associated increased fracture risk, vascular calcification, and accelerated mortality fracture risk. Peritoneal dialysis, however, bears a lower risk than hemodialysis (HD). The approach to CKD-MBD prophylaxis and treatment in the elderly PD patient is similar to other CKD patients, with some important differences. Avoidance of hypercalcemia, hyperphosphatemia, and hyperparathyroidism is important, as in other CKD groups, and is generally easier to attain. Calcium-free phosphate binders are recommended for normocalcemic and hypercalcemic patients. Normalization of vitamin D levels to > 75 nmol/L (> 30 pg/L) and low-dose active vitamin D therapy is recommended for all patients. Hyperparathryoidism is to be avoided by using active vitamin D and cinacalcet. Particular attention should be paid to treating protein malnutrition. Fracture prophylaxis (exercise, use of walkers, dwelling modifications) are important. Hypomagnesemia is common in PD and can be treated with magnesium supplements. Vitamin K deficiency is also common and has been identified as a cause of vascular calcification. Accordingly, warfarin treatment for this age group is problematic. CONCLUSION: While treatment principles are similar to other dialysis patient groups, physicians should be aware of the special problems of the elderly group.
Subject(s)
Bone Density/physiology , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/prevention & control , Dietary Supplements , Peritoneal Dialysis/adverse effects , Renal Insufficiency, Chronic/therapy , Aged , Aged, 80 and over , Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/prevention & control , Calcium/therapeutic use , Exercise/physiology , Female , Follow-Up Studies , Fractures, Spontaneous/etiology , Fractures, Spontaneous/prevention & control , Geriatric Assessment/methods , Humans , Magnesium/therapeutic use , Male , Peritoneal Dialysis/methods , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/mortality , Risk Assessment , Treatment Outcome , Vitamin D/therapeutic use , Vitamin K/therapeutic useABSTRACT
BACKGROUND: The purpose of this study was to assess the effects of the durations of cast immobilization and non-weight-bearing periods, and decreases in vigorous physical activity (VPA) on bone mineral parameters in a pediatric population treated for a lower-limb fracture. METHODS: Fifty children and teenagers who had undergone a cast-mediated immobilization for a leg or ankle fracture were prospectively recruited. The durations of cast immobilization and non-weight-bearing periods were recorded for each participant. Dual-energy x-ray absorptiometry scans were performed at the time of fracture treatment (baseline) and at cast removal. Physical activity during cast immobilization was assessed using accelerometers. RESULTS: A strong negative correlation was found between the total duration of cast immobilization and decreases in both calcaneal bone mineral density (BMD) (r=-0.497) and total lower-limb bone mineral content (BMC) (r=-0.405). A strong negative correlation was also noted between the durations of the non-weight-bearing periods and alterations in calcaneal BMD (r=-0.420). No apparent correlations were found between lower BMD and BMC and decreased VPA. CONCLUSIONS: Bone mineral loss was correlated to the total duration of cast immobilization for all measurement sites on the affected leg, whereas it was only correlated to the durations of non-weight-bearing periods for calcaneal BMD and total lower-limb BMC. However, no correlations were noted between bone mineral loss and decreased VPA.
Subject(s)
Bone Demineralization, Pathologic , Fracture Fixation , Fractures, Bone/therapy , Leg Bones , Absorptiometry, Photon/methods , Adolescent , Bone Demineralization, Pathologic/diagnosis , Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/prevention & control , Bone Density , Casts, Surgical , Child , Child, Preschool , Female , Fracture Fixation/adverse effects , Fracture Fixation/instrumentation , Fracture Fixation/methods , Fractures, Bone/diagnosis , Humans , Leg Bones/injuries , Leg Bones/pathology , Longitudinal Studies , Male , Motor Activity/physiology , Switzerland , Time Factors , Weight-BearingABSTRACT
Evidences have shown that pulsed electromagnetic fields (PEMFs) can partially prevent bone loss in streptozotocin (STZ)-induced diabetic rats. However, the precise mechanisms accounting for these favorable effects are unclear. This study aimed to investigate the effects of PEMFs on bone mass and receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) and Wnt/ß-catenin signaling pathway in STZ rats. Thirty 3-month-old Sprague Dawley rats were randomly divided into the following three groups (n = 10): control group (injection of saline vehicle), DM group (injection of STZ), and PEMFs group (injection of STZ + PEMFs exposure). One week following injection of STZ, rats in the PEMFs group were subject to PEMFs stimulus for 40 min/day, 5 days/week, and lasted for 12 weeks. After 12 week intervention, the results showed that PEMFs increased serum bone-specific alkaline phosphatase level and bone mineral density, and inhibited deterioration of bone microarchitecture and strength in STZ rats. Furthermore, PEMFs up-regulated the mRNA expressions of low-density lipoprotein receptor-related protein 5, ß-catenin and runt-related gene 2 (Runx2), and down-regulated dickkopf1 in STZ rats. However, mRNA expressions of RANKL and OPG were not affected by PEMFs. PEMFs can prevent the diabetes-induced bone loss and reverse the deterioration of bone microarchitecture and strength by restoring Runx2 expression through regulation of Wnt/ß-catenin signaling, regardless of its no glucose lowering effect.
Subject(s)
Bone Demineralization, Pathologic/prevention & control , Diabetes Complications/prevention & control , Diabetes Mellitus, Experimental/complications , Magnetic Field Therapy/methods , RANK Ligand/metabolism , Wnt Signaling Pathway/physiology , Animals , Antibiotics, Antineoplastic/pharmacology , Core Binding Factor Alpha 1 Subunit/metabolism , Diabetes Mellitus, Experimental/chemically induced , Female , Male , Rats , Rats, Sprague-Dawley , Streptozocin/pharmacologyABSTRACT
Bone loss can result from bed rest, space flight, spinal cord injury or age-related hormonal changes. Current bone loss mitigation techniques include pharmaceutical interventions, exercise, pulsed ultrasound targeted to bone and whole body vibration. In this study, we attempted to mitigate paralysis-induced bone loss by applying focused ultrasound to the midbelly of a paralyzed muscle. We employed a mouse model of disuse that uses onabotulinumtoxinA-induced paralysis, which causes rapid bone loss in 5 d. A focused 2 MHz transducer applied pulsed exposures with pulse repetition frequency mimicking that of motor neuron firing during walking (80 Hz), standing (20 Hz), or the standard pulsed ultrasound frequency used in fracture healing (1 kHz). Exposures were applied daily to calf muscle for 4 consecutive d. Trabecular bone changes were characterized using micro-computed tomography. Our results indicated that application of certain focused pulsed ultrasound parameters was able to mitigate some of the paralysis-induced bone loss.
Subject(s)
Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/prevention & control , Muscle, Skeletal/diagnostic imaging , Paralysis/complications , Ultrasonic Therapy/methods , Animals , Bone Demineralization, Pathologic/diagnostic imaging , Disease Models, Animal , Female , Mice , Mice, Inbred C57BL , Tibia/diagnostic imaging , Ultrasonography , X-Ray Microtomography/methodsABSTRACT
As the Mediterranean diet (and particularly olive oil) has been associated with bone health, we investigated the impact of extra virgin oil as a source of polyphenols on bone metabolism. In that purpose sham-operated (SH) or ovariectomized (OVX) mice were subjected to refined or virgin olive oil. Two supplementary OVX groups were given either refined or virgin olive oil fortified with vitamin D3, to assess the possible synergistic effects with another liposoluble nutrient. After 30 days of exposure, bone mineral density and gene expression were evaluated. Consistent with previous data, ovariectomy was associated with increased bone turnover and led to impaired bone mass and micro-architecture. The expression of oxidative stress markers were enhanced as well. Virgin olive oil fortified with vitamin D3 prevented such changes in terms of both bone remodeling and bone mineral density. The expression of inflammation and oxidative stress mRNA was also lower in this group. Overall, our data suggest a protective impact of virgin olive oil as a source of polyphenols in addition to vitamin D3 on bone metabolism through improvement of oxidative stress and inflammation.
Subject(s)
Bone Demineralization, Pathologic/prevention & control , Bone Density/drug effects , Plant Oils/therapeutic use , Vitamin D/therapeutic use , Animals , Body Composition/drug effects , Bone Density Conservation Agents/therapeutic use , Bone and Bones/metabolism , Bone and Bones/pathology , Diet, Mediterranean , Dietary Fats, Unsaturated/therapeutic use , Drug Synergism , Estrogens/deficiency , Female , Mice , Mice, Inbred C57BL , Olive Oil , Ovariectomy , Oxidative Stress/drug effects , Polyphenols/metabolismABSTRACT
Osteoporosis is a leading cause of morbidity and mortality in the elderly and influences quality of life, as well as life expectancy. Currently, there is a growing interest among the medical scientists in search of specific nutrients and/or bioactive compounds of natural origin for the prevention of disease and maintenance of bone health. Although calcium and vitamin D have been the primary focus of nutritional prevention of osteoporosis, a recent research has clarified the importance of several additional nutrients and food constituents. Based on this review of the literature, supplementation with vitamins B, C, K, and silicon could be recommended for proper maintenance of bone health, although further clinical studies are needed. The results of studies on long-chain polyunsaturated fatty acids, potassium, magnesium, copper, selenium, and strontium are not conclusive, although studies in vitro and in animal models are interesting and promising (AU)
La osteoporosis es una de las principales causas de morbimortalidad en ancianos y tiene repercusiones en la calidad y esperanza de vida. Actualmente existe un interés creciente por parte de los investigadores médicos en los nutrientes y compuestos bioactivos de origen natural que puede ser útiles para la prevención de la enfermedad y el mantenimiento de la salud ósea. Si bien el calcio y la vitamina D han sido los nutrientes más destacados en la prevención de la osteoporosis, investigaciones recientes han aportado información sobre la importancia de otros nutrientes y componentes alimentarios. En base a esta revisión de la literatura, se puede recomendar la suplementación con vitaminas B, C, K y silicio para el mantenimiento adecuado de la salud ósea, aunque se necesitan más estudios clínicos. Los resultados de estudios sobre la cadena larga de ácidos grasos poliinsaturados, potasio, magnesio, cobre, selenio, estroncio no son concluyentes, aunque los estudios in vitro y en modelos animales son interesantes y prometedores (AU)
Subject(s)
Humans , Bone Demineralization, Pathologic/prevention & control , Osteoporosis/prevention & control , Nutrients/analysis , Aging , Elderly Nutrition , Vitamin K/therapeutic use , Ascorbic Acid/therapeutic use , Thiamine/therapeutic use , Silicon/therapeutic useABSTRACT
OBJECTIVE: To compare the effects of calcitonin, etidronate, and alendronate in preventing bone loss during the first 2 years after heart transplant. METHODS: A total of 222 heart transplant recipients (mean [SD] age, 52.4 [10] years, 85% male) were evaluated. Patients with normal bone mineral density (reference group, n = 102) received 1000 mg/d calcium plus 800 IU/d vitamin D3. The rest were assigned to 200 IU/d of calcitonin (n=42), 400 mg/d etidronate orally for 14 days quarterly (n = 33), or 10 mg/d alendronate (n = 45). All patients received calcium and vitamin D. Bone mineral density was assessed by dual-energy x-ray absorptiometry in the lumbar spine, the entire femur, and the femoral neck at baseline and 6, 12, and 24 months after transplant. RESULTS: At 2 years after transplant, bone mineral density in the lumbar spine had decreased in the reference group (-3.07%), calcitonin group (-0.93%), and etidronate group (-1.87%) but not in the alendronate group (+4.9%; P <.001). After 2 years, bone mineral density in the entire femur decreased in all groups (-3.2% in the reference group, -3.6% in the calcitonin group, -4.6% in the etidronate group, and -0.5% in the alendronate group) but bone loss was significantly lower in the alendronate group (P <.001). Bone mineral density in the femoral neck also decreased in all groups. The incidence of vertebral fractures did not differ among groups. Adverse events were similar between groups. CONCLUSIONS: Alendronate therapy in heart transplant recipients was associated with a significant increase in bone mineral density in the lumbar spine and less bone loss at the hip.
Subject(s)
Alendronate/therapeutic use , Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/prevention & control , Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Calcitonin/therapeutic use , Calcium/therapeutic use , Etidronic Acid/therapeutic use , Heart Transplantation/adverse effects , Vitamin D/therapeutic use , Absorptiometry, Photon , Adolescent , Adult , Aged , Analysis of Variance , Chi-Square Distribution , Female , Humans , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Treatment OutcomeABSTRACT
A variety of physiological changes are experienced by astronauts during both short- and long-duration space missions. These include space motion sickness, spatial disorientation, orthostatic hypotension, muscle atrophy, bone demineralization, increased cancer risk, and a compromised immune system. This review focuses on countermeasures used to moderate these changes, particularly exercise devices that have been used by National Aeronautics and Space Administration astronauts over the past six decades as countermeasures to muscle atrophy and bone loss. The use of these devices clearly has shown that a microgravity environment places unusual demands on both the equipment and the human users. While it is of paramount importance to overcome microgravity-induced musculoskeletal deconditioning, it also is imperative that the exercise system (i) is small and lightweight, (ii) does not require an external power source, (iii) produces 1g-like benefits to both bones and muscles, (iv) requires relatively short durations of exercise, and (v) does not affect the surrounding structure or environment negatively through noise and/or induced vibrations.
Subject(s)
Equipment Design , Exercise/physiology , Muscle, Skeletal/pathology , Sports Equipment , Weightlessness/adverse effects , Atrophy/prevention & control , Bone Demineralization, Pathologic/prevention & control , Humans , Space FlightABSTRACT
No disponible
Subject(s)
Humans , Hyperparathyroidism, Primary/drug therapy , Diphosphonates/therapeutic use , Bone Density Conservation Agents/therapeutic use , Parathyroidectomy , Bone Demineralization, Pathologic/prevention & controlABSTRACT
La deficiencia de vitamina D, definida como valores de 25-hidroxivitamina D < 20-30 ng/ml, es un problema prevalente en la población general. Además de relacionarse clásicamente con la enfermedad musculoesquelética, el déficit de vitamina D se ha relacionado con enfermedades autoinmunes, cáncer, enfermedades metabólicas y enfermedades cardiovasculares. La hipertensión arterial, como principal factor de riesgo cardiovascular, también se ha relacionado con el déficit de vitamina D, llevando a converger dos grandes problemas de salud prevalentes en la población mundial. Por tanto, este artículo revisa aquellos estudios más importantes que vinculan ambas patologías, los mecanismos descritos que las relacionan y la evidencia actual acerca del efecto que la suplementación de vitamina D podría tener sobre la hipertensión arterial (AU)
Low levels of vitamin D, defined as levels of 25-hydroxyvitamin D < 20-30 ng/ml, is a prevalent problem in the general population. Besides the classic relation with musculoskeletal disease, vitamin D has been also related to autoimmune diseases, cancer, metabolic diseases or cardiovascular diseases. High blood pressure, as the main cardiovascular risk factor, also has been related to vitamin D deficiency, constituting two prevalent worldwide health problems. Therefore, this article reviews the most important studies that combine both pathologies, the biological mechanism that relate them and the current evidence about the effect of vitamin D supplementation on hypertension (AU)
Subject(s)
Humans , Hypertension/physiopathology , Vitamin D Deficiency/complications , Cardiovascular Diseases/prevention & control , Risk Factors , Bone Demineralization, Pathologic/prevention & control , Vitamin D/administration & dosageABSTRACT
FUNDAMENTOS La importancia de la ingesta de calcio viene dada por su papel en la prevención de la aparición de la osteoporosis. Se ha relacionado en diversos estudios su mayor prevalencia, así como la de las fracturas, con un déficit en el aporte en la dieta, por lo que una ingesta adecuada desempeña un papel importante en la prevención e incluso en el tratamiento de los problemas citados. Nos marcamos como objetivos conocer el aporte de calcio en la dieta a través de la ingesta de lácteos en mujeres de Gran Canaria, así como el porcentaje de ellas que toman tratamientos con calcio y con antiresortivos. MATERIAL Y MÉTODOS Estudio transversal. Se realizó una encuesta de los hábitos alimenticios en cuanto a la ingesta de calcio en 3 zonas básicas de salud de la isla de Gran Canaria de manera aleatoria a mujeres con edades superiores a 25 años (no embarazadas), y se obtuvieron datos de su historial sobre el empleo de suplementos de calcio y/o tratamiento farmacológico de osteoporosis. RESULTADOS Se obtuvieron 298 encuestas. La edad media fue de 55,06±16,03, el 44,3% menores de 50 años, mientras que las mayores de 50 años fueron el 55,7%. El 8,9% de las mujeres tomaban un suplemento de calcio, y el 5,3% tomaban un bifosfonato. El consumo medio de calcio fue 830 ± 434 mg. Analizandolo entre los dos grupos de mujeres (menores y mayores de 50 años) mediante la t de student no se obtuvieron diferencias estadísticamente significativas. Hicimos un análisis de regresión lineal para la edad, y obtuvimos que por cada año más de edad en la mujer se consumían 6,9mg más de calcio, siendo este resultado estadísticamente significativo (p<0,001). CONCLUSIONES De acuerdo con las ingesta dietéticas recomendadas para la población española, el aporte de calcio en la población canaria a partir de lácteos es adecuado. Según aumenta la edad de la mujer, se aumenta el consumo de productos lácteos, con lo cual, a mayor edad mayor consumo. Es nuestro deber incentivar el consumo de calcio en edades más tempranas para alcanzar un mayor pico óseo (AU)
BASICS The importance of calcium intake is due to its role in preventing the onset of osteoporosis. Has been related in most prevalence studies, as well as fractures, with a shortfall in supply in the diet, so that an adequate intake plays an important role in preventing and even treating these problems. We set as objective to know the contribution of calcium in the diet through dairy intake in women of Gran Canaria, and the percentage of those who take treatment with calcium and antiresorptive. METERIAL AND METHODS Cross-sectional study. A survey of dietary habits in terms of calcium intake in 3 health districts of the island of Gran Canaria at random to women aged over 25 years (not pregnant), and data were obtained from history on the use of calcium supplements and / or pharmacological treatment of osteoporosis. RESULTS 298 surveys were obtained. The mean age was 55.06 ± 16.03, 44.3% younger than 50 years, while those over 50 years was 55.7%. 8.9% of women taking a calcium supplement, and 5.3% were taking a bisphosphonate. The mean calcium intake was 830 ± 434 mg. Analyzed between the two groups of women (younger and older than 50 years) by Students t differences were not statistically significant. We did a linear regression analysis age, and we got that for each year of age in women is 6.9 mg consumed more calcium and this was statistically significant (p <0.001). CONCLUSIONS According to the recommended dietary intake for the Spanish population, the contribution of calcium in the Canary Islands population from milk is adequa te. Increa - sing age of women, increasing the consumption of dairy products, thereby, increase with age consumption. It is our duty to promote the consumption of calcium at a younger age to reach a higher peak bone (AU)